Symbols / MBRX $2.05 +0.49%
MBRX Chart
About
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activator of transcription for brain tumors and pancreatic and other cancers. In addition, it is developing WP1122 portfolio, such as WP1122, WP1096, and WP1097 designed to exploit the uses of inhibitors of glycolysis comprising 2-deoxy-D-glucose for the treatment of pathogenic viruses and various cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 6.31M |
| Enterprise Value | -2.14M | Income | -51.41M | Sales | — |
| Book/sh | -13.60 | Cash/sh | 3.29 | Dividend Yield | — |
| Payout | 0.00% | Employees | 17 | IPO | — |
| P/E | — | Forward P/E | -0.02 | PEG | — |
| P/S | — | P/B | -0.15 | P/C | — |
| EV/EBITDA | 0.09 | EV/Sales | — | Quick Ratio | 1.18 |
| Current Ratio | 1.39 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -49.75 | EPS next Y | -121.25 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-13 16:00 | ROA | -69.18% |
| ROE | — | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 3.08M |
| Shs Float | 2.02M | Short Float | 6.30% | Short Ratio | 0.85 |
| Short Interest | — | 52W High | 33.00 | 52W Low | 1.79 |
| Beta | 1.74 | Avg Volume | 187.01K | Volume | 100.11K |
| Target Price | $21.00 | Recom | Strong_buy | Prev Close | $2.04 |
| Price | $2.05 | Change | 0.49% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$21.00
Mean price target
2. Current target
$2.05
Latest analyst target
3. DCF / Fair value
$-71.18
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.05
Low
$10.00
High
$31.00
Mean
$21.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-11 | main | HC Wainwright & Co. | Buy → Buy | $22 |
| 2025-09-10 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2025-08-27 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2025-06-18 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2025-03-25 | up | Maxim Group | Hold → Buy | $4 |
| 2025-03-25 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2025-03-24 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2025-03-03 | main | HC Wainwright & Co. | Buy → Buy | $8 |
| 2024-11-12 | main | Maxim Group | Buy → Buy | $8 |
| 2024-04-12 | main | Roth MKM | Buy → Buy | $40 |
| 2024-03-26 | main | Maxim Group | Buy → Buy | $20 |
| 2023-12-14 | init | HC Wainwright & Co. | — → Buy | $3 |
| 2023-04-18 | main | Roth MKM | — → Buy | $16 |
| 2023-03-24 | reit | Oppenheimer | — → Outperform | $5 |
- Leukemia trial update: Moleculin CEO explains MIRACLE drug study - Stock Titan Wed, 11 Mar 2026 13
- Why Did MBRX Stock Climb 14% Today? - Stocktwits Wed, 18 Feb 2026 18
- Moleculin Stock Plunges On $8.3 Million Warrant Exercise - Nasdaq hu, 19 Feb 2026 08
- Moleculin Announces Reverse Stock Split - Yahoo Finance Wed, 26 Nov 2025 08
- $MBRX stock is down 17% today. Here's what we see in our data. - Quiver Quantitative Wed, 17 Dec 2025 08
- MBRX Stock Reverse Split 2025 Amid Biotech Bankruptcies: Analysts Remain Bullish - Bitget Sun, 30 Nov 2025 08
- Moleculin Biotech stock falls after warrant exercise agreement - Investing.com Wed, 10 Dec 2025 08
- Early trial in children finds brain tumor therapy sparks immune response - Stock Titan Wed, 17 Dec 2025 08
- HC Wainwright & Co. Maintains Moleculin Biotech (MBRX) Buy Recommendation - Nasdaq hu, 11 Dec 2025 08
- Moleculin Biotech, Inc. Announces 1-for-25 Reverse Stock Split Effective December 1, 2025 - Quiver Quantitative Wed, 26 Nov 2025 08
- Moleculin Biotech (MBRX) Upgraded to Buy: Here's What You Should Know - Yahoo Finance Wed, 17 Sep 2025 07
- Moleculin Biotech (Nasdaq: MBRX) enters warrant exercise deals for approx $6.5M - Stock Titan Wed, 10 Dec 2025 08
- Moleculin (Nasdaq: MBRX) sets Q1 2026 finish for first 45 patients; unblinding after - Stock Titan hu, 13 Nov 2025 08
- Moleculin’s $8.3M warrant deal: 2,122,652 shares now, 6,367,956 new warrants - Stock Titan hu, 19 Feb 2026 08
- Moleculin (NASDAQ: MBRX) presents Phase 3 MIRACLE AML trial of AnnAraC regimen - Stock Titan hu, 30 Oct 2025 07
Insider Transactions
| Date | Shares | Url | Text | Insider | Position | Transaction | Start Date | Ownership | Value |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 8750 | — | — | PICKER DONALD H | Officer | — | 2025-11-04 00:00:00 | D | nan |
| 1 | 28750 | — | — | KLEMP WALTER V. | Chief Executive Officer | — | 2025-11-04 00:00:00 | D | nan |
| 2 | 20625 | — | — | FOSTER JONATHAN P. | Chief Financial Officer | — | 2025-11-04 00:00:00 | D | nan |
| 3 | 675675 | — | Purchase at price 0.37 per share. | KLEMP WALTER V. | Chief Executive Officer | — | 2025-06-23 00:00:00 | D | 250000.0 |
| 4 | 270270 | — | Purchase at price 0.37 per share. | FOSTER JONATHAN P. | Chief Financial Officer | — | 2025-06-23 00:00:00 | D | 100000.0 |
| 5 | 2844 | — | — | PICKER DONALD H | Officer | — | 2025-06-20 00:00:00 | D | nan |
| 6 | 12740 | — | — | KLEMP WALTER V. | Chief Executive Officer | — | 2025-06-20 00:00:00 | D | nan |
| 7 | 7039 | — | — | FOSTER JONATHAN P. | Chief Financial Officer | — | 2025-06-20 00:00:00 | D | nan |
| 8 | 1667 | — | — | KLEMP WALTER V. | Chief Executive Officer | — | 2025-06-16 00:00:00 | D | nan |
| 9 | 833 | — | — | FOSTER JONATHAN P. | Chief Financial Officer | — | 2025-06-16 00:00:00 | D | nan |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -30.80M | -27.95M | -31.84M | -29.53M |
| TotalUnusualItems | 4.29M | -1.55M | 1.33M | 6.73M |
| TotalUnusualItemsExcludingGoodwill | 4.29M | -1.55M | 1.33M | 6.73M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -21.76M | -29.77M | -29.02M | -15.89M |
| ReconciledDepreciation | 126.00K | 127.00K | 130.00K | 164.00K |
| EBITDA | -26.52M | -29.50M | -30.51M | -22.80M |
| EBIT | -26.64M | -29.63M | -30.64M | -22.97M |
| NetInterestIncome | 550.00K | 1.37M | 240.00K | 306.00K |
| InterestIncome | 550.00K | 1.37M | 240.00K | 306.00K |
| NormalizedIncome | -26.05M | -28.21M | -30.36M | -22.62M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -21.76M | -29.77M | -29.02M | -15.89M |
| TotalExpenses | 26.64M | 29.63M | 30.64M | 22.97M |
| TotalOperatingIncomeAsReported | -26.64M | -29.63M | -30.64M | -22.97M |
| DilutedAverageShares | 137.72K | 79.02K | 76.28K | 71.67K |
| BasicAverageShares | 137.72K | 79.02K | 76.28K | 71.67K |
| DilutedEPS | -158.00 | -376.75 | -378.75 | -221.25 |
| BasicEPS | -158.00 | -376.75 | -378.75 | -221.25 |
| DilutedNIAvailtoComStockholders | -21.76M | -29.77M | -29.02M | -15.89M |
| NetIncomeCommonStockholders | -21.76M | -29.77M | -29.02M | -15.89M |
| NetIncome | -21.76M | -29.77M | -29.02M | -15.89M |
| NetIncomeIncludingNoncontrollingInterests | -21.76M | -29.77M | -29.02M | -15.89M |
| NetIncomeContinuousOperations | -21.76M | -29.77M | -29.02M | -15.89M |
| PretaxIncome | -21.76M | -29.77M | -29.02M | -15.89M |
| OtherIncomeExpense | 4.33M | -1.51M | 1.38M | 6.77M |
| OtherNonOperatingIncomeExpenses | 43.00K | 48.00K | 40.00K | 40.00K |
| GainOnSaleOfSecurity | 4.29M | -1.55M | 1.33M | 6.73M |
| NetNonOperatingInterestIncomeExpense | 550.00K | 1.37M | 240.00K | 306.00K |
| InterestIncomeNonOperating | 550.00K | 1.37M | 240.00K | 306.00K |
| OperatingIncome | -26.64M | -29.63M | -30.64M | -22.97M |
| OperatingExpense | 26.64M | 29.63M | 30.64M | 22.97M |
| DepreciationAmortizationDepletionIncomeStatement | 126.00K | 127.00K | 130.00K | 164.00K |
| DepreciationAndAmortizationInIncomeStatement | 126.00K | 127.00K | 130.00K | 164.00K |
| ResearchAndDevelopment | 17.73M | 19.49M | 18.97M | 14.42M |
| SellingGeneralAndAdministration | 8.79M | 10.02M | 11.54M | 8.39M |
| GeneralAndAdministrativeExpense | 8.79M | 10.02M | 11.54M | 8.39M |
| OtherGandA | 8.79M | 10.02M | 11.54M | 8.39M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 135.16K | 89.10K | 76.34K | 76.21K |
| ShareIssued | 135.16K | 89.10K | 76.34K | 76.21K |
| TotalDebt | 478.00K | 574.00K | 451.00K | 159.00K |
| TangibleBookValue | -5.17M | 14.93M | 41.04M | 67.84M |
| InvestedCapital | 5.98M | 26.07M | 52.19M | 78.99M |
| WorkingCapital | -165.00K | 19.46M | 40.78M | 68.88M |
| NetTangibleAssets | -5.17M | 14.93M | 41.04M | 67.84M |
| CapitalLeaseObligations | 478.00K | 574.00K | 451.00K | 159.00K |
| CommonStockEquity | 5.98M | 26.07M | 52.19M | 78.99M |
| TotalCapitalization | 5.98M | 26.07M | 52.19M | 78.99M |
| TotalEquityGrossMinorityInterest | 5.98M | 26.07M | 52.19M | 78.99M |
| StockholdersEquity | 5.98M | 26.07M | 52.19M | 78.99M |
| GainsLossesNotAffectingRetainedEarnings | -41.00K | -9.00K | 12.00K | 41.00K |
| OtherEquityAdjustments | -41.00K | -9.00K | 12.00K | 41.00K |
| RetainedEarnings | -153.37M | -131.60M | -101.83M | -72.81M |
| AdditionalPaidInCapital | 159.38M | 157.65M | 153.99M | 151.73M |
| CapitalStock | 3.00K | 33.00K | 29.00K | 29.00K |
| CommonStock | 3.00K | 33.00K | 29.00K | 29.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 10.95M | 12.14M | 5.23M | 5.10M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 5.59M | 5.33M | 412.00K | 1.48M |
| DerivativeProductLiabilities | 5.23M | 4.86M | 77.00K | 1.41M |
| LongTermDebtAndCapitalLeaseObligation | 358.00K | 474.00K | 335.00K | 63.00K |
| LongTermCapitalLeaseObligation | 358.00K | 474.00K | 335.00K | 63.00K |
| CurrentLiabilities | 5.36M | 6.82M | 4.82M | 3.62M |
| CurrentDebtAndCapitalLeaseObligation | 120.00K | 100.00K | 116.00K | 96.00K |
| CurrentCapitalLeaseObligation | 120.00K | 100.00K | 116.00K | 96.00K |
| PayablesAndAccruedExpenses | 5.24M | 6.71M | 4.70M | 3.53M |
| CurrentAccruedExpenses | 3.08M | 4.16M | 2.52M | 2.05M |
| Payables | 2.16M | 2.56M | 2.18M | 1.47M |
| DuetoRelatedPartiesCurrent | 130.00K | 60.00K | 86.00K | 109.00K |
| AccountsPayable | 2.03M | 2.50M | 2.10M | 1.36M |
| TotalAssets | 16.93M | 38.22M | 57.42M | 84.09M |
| TotalNonCurrentAssets | 11.73M | 11.94M | 11.83M | 11.59M |
| GoodwillAndOtherIntangibleAssets | 11.15M | 11.15M | 11.15M | 11.15M |
| OtherIntangibleAssets | 11.15M | 11.15M | ||
| NetPPE | 583.00K | 796.00K | 678.00K | 445.00K |
| AccumulatedDepreciation | -1.02M | -896.00K | -769.00K | -638.00K |
| GrossPPE | 1.60M | 1.69M | 1.45M | 1.08M |
| OtherProperties | 424.00K | 524.00K | 403.00K | 107.00K |
| MachineryFurnitureEquipment | 1.18M | 1.17M | 1.04M | 976.00K |
| CurrentAssets | 5.19M | 26.27M | 45.60M | 72.50M |
| PrepaidAssets | 896.00K | 2.62M | 2.43M | 1.55M |
| Receivables | 20.00K | 99.00K | 22.00K | 45.00K |
| OtherReceivables | 16.00K | 95.00K | 2.00K | 23.00K |
| DuefromRelatedPartiesCurrent | 4.00K | 4.00K | 20.00K | 22.00K |
| CashCashEquivalentsAndShortTermInvestments | 4.28M | 23.55M | 43.15M | 70.90M |
| CashAndCashEquivalents | 4.28M | 23.55M | 43.15M | 70.90M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -23.88M | -23.71M | -27.71M | -18.97M |
| IssuanceOfCapitalStock | 4.66M | 4.17M | 0.00 | 74.68M |
| CapitalExpenditure | -13.00K | -124.00K | -67.00K | -19.00K |
| InterestPaidSupplementalData | 0.00 | |||
| IncomeTaxPaidSupplementalData | 15.00K | |||
| EndCashPosition | 4.28M | 23.55M | 43.15M | 70.90M |
| BeginningCashPosition | 23.55M | 43.15M | 70.90M | 15.17M |
| EffectOfExchangeRateChanges | -32.00K | -21.00K | -29.00K | -24.00K |
| ChangesInCash | -19.24M | -19.57M | -27.73M | 55.75M |
| FinancingCashFlow | 4.63M | 4.14M | -23.00K | 74.72M |
| CashFlowFromContinuingFinancingActivities | 4.63M | 4.14M | -23.00K | 74.72M |
| NetOtherFinancingCharges | -26.00K | -25.00K | -23.00K | -23.00K |
| ProceedsFromStockOptionExercised | 1.00K | 0.00 | 0.00 | 63.00K |
| NetCommonStockIssuance | 4.66M | 4.17M | 0.00 | 74.68M |
| CommonStockIssuance | 4.66M | 4.17M | 0.00 | 74.68M |
| InvestingCashFlow | -13.00K | -124.00K | -67.00K | -19.00K |
| CashFlowFromContinuingInvestingActivities | -13.00K | -124.00K | -67.00K | -19.00K |
| NetPPEPurchaseAndSale | -13.00K | -124.00K | -67.00K | -19.00K |
| SaleOfPPE | 0.00 | |||
| PurchaseOfPPE | -13.00K | -124.00K | -67.00K | -19.00K |
| OperatingCashFlow | -23.86M | -23.59M | -27.64M | -18.95M |
| CashFlowFromContinuingOperatingActivities | -23.86M | -23.59M | -27.64M | -18.95M |
| ChangeInWorkingCapital | 231.00K | 1.62M | 224.00K | 1.04M |
| ChangeInPayablesAndAccruedExpense | -1.58M | 1.89M | 1.08M | 607.00K |
| ChangeInAccruedExpense | -1.11M | 1.49M | 350.00K | 372.00K |
| ChangeInPayable | -468.00K | 403.00K | 731.00K | 235.00K |
| ChangeInAccountPayable | -468.00K | 403.00K | 731.00K | 235.00K |
| ChangeInPrepaidAssets | 1.81M | -272.00K | -857.00K | 431.00K |
| OtherNonCashItems | 103.00K | 891.00K | 92.00K | 96.00K |
| StockBasedCompensation | 1.73M | 1.98M | 2.27M | 2.37M |
| DepreciationAmortizationDepletion | 126.00K | 127.00K | 130.00K | 164.00K |
| DepreciationAndAmortization | 126.00K | 127.00K | 130.00K | 164.00K |
| OperatingGainsLosses | -4.29M | 1.55M | -1.33M | -6.73M |
| GainLossOnInvestmentSecurities | -4.29M | 1.55M | -1.33M | -6.73M |
| GainLossOnSaleOfPPE | 0.00 | |||
| NetIncomeFromContinuingOperations | -21.76M | -29.77M | -29.02M | -15.89M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for MBRX
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|